Headlands Technologies LLC Takes Position in BioNTech SE Sponsored ADR $BNTX

Key Points

• Headlands Technologies established a new BioNTech position in the second quarter, purchasing 27,087 shares valued at approximately $2.52 million. Institutional investors collectively own 15.52% of BNTX.
• BioNTech reported a quarterly loss of $2.53 per share versus the $2.40 analyst estimate, while revenue fell 59.5% year over year to $122.31 million, below expectations. The company has also authorized a $1 billion share buyback, covering up to 4.2% of outstanding shares.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $127.81. However, investors face mixed catalysts: FDA approval of the next-season COMIRNATY vaccine contrasts with the termination of a Phase 2 colorectal cancer vaccine trial and concerns about COVID-19 vaccine demand.

Headlands Technologies LLC purchased a new position in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 27,087 shares of the company's stock, valued at approximately $2,520,000.

A number of other hedge funds also recently bought and sold shares of BNTX. Pictet Asset Management Holding SA increased its holdings in shares of BioNTech by 41.6% in the 4th quarter. Pictet Asset Management Holding SA now owns 88,838 shares of the company's stock worth $8,457,000 after buying an additional 26,119 shares during the last quarter. Monaco Asset Management SAM bought a new position in shares of BioNTech in the 4th quarter valued at about $1,594,000. Hsbc Holdings PLC bought a new position in shares of BioNTech in the 4th quarter valued at about $4,969,000. BNP Paribas Financial Markets grew its position in BioNTech by 43.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company's stock worth $150,235,000 after acquiring an additional 474,796 shares in the last quarter. Finally, Bank of America Corp DE grew its position in BioNTech by 22.6% in the first quarter. Bank of America Corp DE now owns 903,029 shares of the company's stock worth $80,261,000 after acquiring an additional 166,432 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Price Performance

BNTX opened at $102.07 on Monday. The business has a fifty day moving average of $95.40 and a 200 day moving average of $95.79. The stock has a market cap of $25.81 billion, a P/E ratio of -13.04 and a beta of 1.27. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a 52-week low of $79.52 and a 52-week high of $124.00.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts' consensus estimates of ($2.40) by ($0.13). The business had revenue of $122.31 million during the quarter, compared to analysts' expectations of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The business's revenue for the quarter was down 59.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.60) EPS. As a group, sell-side analysts anticipate that BioNTech SE Sponsored ADR will post -6.33 EPS for the current year.

BioNTech declared that its Board of Directors has approved a share buyback program on Thursday, May 7th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 4.2% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on BNTX. Jefferies Financial Group reiterated a "buy" rating on shares of BioNTech in a report on Monday, June 1st. Citigroup decreased their price target on BioNTech from $130.00 to $125.00 and set a "buy" rating on the stock in a report on Wednesday, August 5th. Weiss Ratings restated a "sell (d-)" rating on shares of BioNTech in a research report on Monday, July 6th. Berenberg Bank dropped their price objective on shares of BioNTech from $155.00 to $140.00 and set a "buy" rating for the company in a research note on Tuesday, May 12th. Finally, Canaccord Genuity Group set a $142.00 target price on shares of BioNTech in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, BioNTech currently has an average rating of "Moderate Buy" and an average target price of $127.81.

Key Headlines Impacting BioNTech

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: The FDA approved Pfizer and BioNTech’s XFG-adapted COMIRNATY vaccine for the 2026–2027 season. Shipping is beginning immediately, potentially supporting near-term seasonal revenue and maintaining the product’s commercial presence. Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
• Positive Sentiment: One investment analysis reiterated a Strong Buy rating, citing momentum in BioNTech’s late-stage oncology pipeline, strategic partnerships, and upcoming catalysts for gotistobart and pumitamig. Expected data at WCLC 2026 could help refocus investor attention on the company’s long-term growth prospects. BioNTech: Reiterating Strong Buy Based On COMIRNATY Variant Expansion And More
• Neutral Sentiment: Options activity was unusually bearish, with put purchases more than doubling typical volume. This signals heightened hedging or speculative downside expectations, but does not by itself establish a change in BioNTech’s fundamentals.
• Negative Sentiment: BioNTech decided to terminate a Phase 2 trial of autogene cevumeran in colorectal cancer. The setback weakens confidence in the company’s personalized mRNA cancer-vaccine strategy and removes a clinical catalyst, overshadowing the COMIRNATY approval. BioNTech to terminate mid-stage trial of mRNA cancer vaccine
• Negative Sentiment: The trial discontinuation triggered a sharp decline in the stock and raised concerns about the risks facing BioNTech’s oncology pipeline. Investors also remain cautious because COVID-19 vaccine demand and competition are pressuring revenue expectations, even as the XFG formulation expands COMIRNATY’s seasonal opportunity. BioNTech Terminates Phase 2 Trial Of Autogene Cevumeran In Colorectal Cancer

About BioNTech

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source